In cases of advanced or metastatic BRAF-mutant thyroid cancer, targeted therapies such as BRAF inhibitors (e.g., vemurafenib and dabrafenib) and MEK inhibitors (e.g., trametinib) have shown promise in clinical trials, offering a therapeutic option for patients with refractory disease [63, 64]. The gene discussed is BRAF; the disease is thyroid cancer.